公开(公告)号：US20250051286A1

公开(公告)日：2025-02-13

申请号：US18721175

申请日：2022-12-16

Applicant: ORIXA THERAPEUTICS LLC

Inventor： Adam Seth HAEBERLE ,  Matteo PANZA ,  James Bernard KRAMER ,  Zahra ASSAR-NOSSONI ,  Matt SIMON

IPC: C07D233/38 ,  A61K31/4025 ,  A61K31/4174 ,  A61K31/4178 ,  A61K31/427 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/506 ,  A61K31/53 ,  A61K45/06 ,  A61P1/04 ,  A61P37/06 ,  A61P43/00 ,  C07D207/50 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D403/14 ,  C07D417/12

Abstract: Disclosed herein are novel small molecules that can be used therapeutically to treat ailments and diseases associated with an over-active or undesired immune response. Specific embodiments include inhibitors of Proteinase 3 (PR3) and Human Neutrophil Elastase (HNE) and methods for their synthesis and use. The agents can be used to treat alpha-1 antitrypsin deficiency and other ailments related to neutrophil activity.